About Opioids, Constipation and RELISTOR (methylnaltrexone bromide)
Opioid analgesics are frequently prescribed for patients with chronic pain. Constipation, a common side effect, occurs in patients receiving opioid therapy. RELISTOR is the first approved medication that specifically targets the underlying cause of opioid-induced constipation in patients with advanced illness receiving palliative care when response to laxative therapy has not been sufficient. Opioids relieve pain by specifically interacting with mu—opioid receptors within the brain and spinal cord. However, opioids also interact with mu—opioid receptors found outside the central nervous system, such as those within the gastrointestinal tract, resulting in constipation that can be debilitating. RELISTOR is a peripherally acting mu—opioid receptor antagonist that does not cross the blood-brain barrier and was specifically designed to block mu-opioid receptors in the GI tract, therefore decreasing the constipating effects of opioid pain medications without affecting their ability to relieve pain.
RELISTOR Subcutaneous Injection was approved in
For more information about RELISTOR, please visit www.RELISTOR.com
Important Safety Information about RELISTOR
RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.
Cases of gastrointestinal (GI) perforation have been reported in adult patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structural integrity in the wall of the GI tract (i.e., cancer, peptic ulcer, Ogilvie's syndrome). Perforations have involved varying regions of the GI tract (e.g., stomach, duodenum, or colon). Use RELISTOR with caution in patients with known or suspected lesions of the GI tract. Advise patients to discontinue therapy with RELISTOR and promptly notify their physician if they develop severe, persistent, or worsening abdominal symptoms.
If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with RELISTOR and consult their physician.
Use of RELISTOR beyond four months has not been studied.
Safety and efficacy of RELISTOR have not been established in pediatric patients.
The most common adverse reactions reported with RELISTOR compared with placebo in clinical trials were abdominal pain (28.5%), flatulence (13.3%), nausea (11.5%), dizziness (7.3%), diarrhea (5.5%), and hyperhidrosis (6.7%).
Please see complete Prescribing Information for RELISTOR.
Salix trades on the NASDAQ Global Select Market under the ticker symbol "SLXP".
For more information, please visit our Website at www.salix.com
or contact the Company at 919-862-1000. Follow us on Twitter
(@SalixPharma) and Facebook (www.facebook.com/SalixPharma).
Information on our Twitter feed, Facebook page and web site is not
incorporated in our
Please Note: The materials provided herein that are not
historical facts are or might constitute forward-looking statements
under the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Although we believe the expectations reflected in
such forward-looking statements are based on reasonable assumptions, our
expectations might not be attained. Forward-looking statements involve
known and unknown risks that could cause actual results to differ
materially from expected results. Factors that could cause actual
results to differ materially from our expectations expressed in the
report include, among others: the unpredictability of the duration and
results of regulatory review of New Drug Applications and
Investigational New Drug Applications, including specifically results of
appeals and Advisory Committees; the high cost and uncertainty of the
research, clinical trials and other development activities involving
pharmaceutical products; the possible impairment of, or inability to
obtain intellectual property rights and the costs of obtaining such
rights from third parties in an increasingly global market; our
dependence on our first seven pharmaceutical products, particularly
Xifaxan and Relistor, and the uncertainty of market acceptance of our
products intense competition, including from generics in an increasingly
global market; general economic conditions; our need to maintain
profitability; the uncertainty of obtaining, and our dependence on,
third parties to manufacture and sell our products; results of ongoing
and any future litigation and investigations and other risk factors
detailed from time to time in our other
Executive Vice President and Chief Financial Officer
G. Michael Freeman, 919-862-1000
Associate Vice President, Investor Relations and Corporate Communications
News Provided by Acquire Media